Prostate Cancer: To Treat or Not to Treat?

被引:6
作者
Abrahamsson, Per-Anders [1 ]
机构
[1] Malmo Univ Hosp, Dept Urol, S-20402 Malmo, Sweden
关键词
Prostate cancer; Prostate-specific antigen; PSA; Active surveillance; LONG-TERM SURVIVAL; SELECTIVE DELAYED INTERVENTION; RADICAL PROSTATECTOMY; ACTIVE SURVEILLANCE; RISK; MANAGEMENT; ANTIGEN; MEN; EXPERIENCE; MORTALITY;
D O I
10.1016/j.eursup.2009.01.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: To treat or not to treat is one of the most difficult dilemmas facing prostate cancer patients, especially elderly men with early prostate cancer or small cancer that is contained within the prostate. Objective: The primary objective of this review is to analyse the treatment options for patients with localised prostate cancer. This information can be considered alongside other important factors like natural history of disease and diagnostic tests. Evidence acquisition: Several randomised and nonrandomised clinical trials published in the literature investigating the natural history of the disease, diagnostic tests, and treatment options for localised prostate cancer have been reviewed for this paper. Evidence synthesis: Analysis of prostate-specific antigen (PSA) kinetics should play a major role in the management of localised prostate cancer. Trials investigating long-term outcomes of active surveillance are under way. Conclusion: Taking all these factors into consideration, the data support active surveillance as an appropriate choice for patients with well-differentiated or moderately differentiated, low-volume prostate cancer who have a life expectancy of <10 yr. Men with higher grade tumours and longer life expectancy may be at excess risk of death from prostate cancer if managed with active surveillance. (c) 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:418 / 423
页数:6
相关论文
共 25 条
  • [1] Albertsen PC, 2005, ACTA ONCOL, V44, P255, DOI 10.1080/02841860410002815
  • [2] Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
    Albertsen, PC
    Hanley, JA
    Gleason, DF
    Barry, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 975 - 980
  • [3] LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER
    ALBERTSEN, PC
    FRYBACK, DG
    STORER, BE
    KOLON, TF
    FINE, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08): : 626 - 631
  • [4] LONG-TERM SURVIVAL AND MORTALITY IN PROSTATE-CANCER TREATED WITH NONCURATIVE INTENT
    AUS, G
    HUGOSSON, J
    NORLEN, L
    [J]. JOURNAL OF UROLOGY, 1995, 154 (02) : 460 - 465
  • [5] Radical prostatectomy versus watchful waiting in early prostate cancer
    Bill-Axelson, A
    Holmberg, L
    Ruutu, M
    Häggman, M
    Andersson, SO
    Bratell, S
    Spångberg, A
    Busch, C
    Nordling, S
    Garmo, H
    Palmgren, J
    Adami, HO
    Norlén, BJ
    Johansson, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) : 1977 - 1984
  • [6] Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study
    Brasso, K
    Friis, S
    Juel, K
    Jorgensen, T
    Iversen, P
    [J]. JOURNAL OF UROLOGY, 1999, 161 (02) : 524 - 528
  • [7] CARTER HB, 2005, AM UR ASS ANN M MAY
  • [8] RESULTS OF CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER
    CHODAK, GW
    THISTED, RA
    GERBER, GS
    JOHANSSON, JE
    ADOLFSSON, J
    JONES, GW
    CHISHOLM, GD
    MOSKOVITZ, B
    LIVNE, PM
    WARNER, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) : 242 - 248
  • [9] Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
    D'Amico, AV
    Chen, MH
    Roehl, KA
    Catalona, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) : 125 - 135
  • [10] Donovan J, 2003, Health Technol Assess, V7, P1